World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
104
Citations
58163
World Ranking
6915
National Ranking
210

Benjamin Besse publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Benjamin Besse sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,080 publications — 96th percentile

96% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Benjamin Besse D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Benjamin Besse sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 104 D-Index — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Benjamin Besse is affiliated with the University of Paris-Saclay in France and has a research focus primarily within the field of medicine, with significant contributions in oncology, pulmonary and respiratory medicine, and cancer research. Their scholarly work spans related subfields including molecular biology and radiology, nuclear medicine, and imaging.

The scientist has authored numerous publications centered on lung cancer treatments and mutations, cancer immunotherapy and biomarkers, cancer genomics and diagnostics, and lung cancer research studies. Additional areas of expertise include lung cancer diagnosis and treatment, colorectal cancer treatments and studies, and the application of radiomics and machine learning in medical imaging.

Frequent publication venues for Benjamin Besse include:

  • Annals of Oncology
  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Cancer Research
  • European Journal of Cancer

Among the notable recent papers are:

  • Sotorasib for Lung Cancers with KRAS p.G12C Mutation, 2021, New England Journal of Medicine
  • Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer, 2020, New England Journal of Medicine
  • Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial, 2022, The Lancet Oncology
  • Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer, 2022, Nature Medicine
  • Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2021, Annals of Oncology

Benjamin Besse has collaborated extensively with several co-authors, with multiple joint publications with David Planchard, Fabrice Barlési, Mihaela Aldea, Laura Mezquita, and Jordi Remón.

Best Publications

  • Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

    Alice T. Shaw;Dong Wan Kim;Kazuhiko Nakagawa;Takashi Seto

  • Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

    Martin Peifer;Lynnette Fernández-Cuesta;Martin L. Sos;Julie George

  • Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

    Robert C Doebele;Alexander Drilon;Alexander Drilon;Luis Paz-Ares;Salvatore Siena

  • Sotorasib for Lung Cancers with KRAS p.G12C Mutation.

    Ferdinandos Skoulidis;Bob T. Li;Grace K. Dy;Timothy J. Price

  • Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

    David Planchard;Egbert F Smit;Harry J M Groen;Julien Mazieres

  • Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

    J. Mazieres;A. Drilon;A. Lusque;L. Mhanna

  • Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

    Fabrice Barlesi;Julien Mazieres;Jean-Philippe Merlio;Didier Debieuvre

  • Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.

    Laura Mezquita;Edouard Auclin;Roberto Ferrara;Melinda Charrier

  • Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer

    Kathryn C. Arbour;Laura Mezquita;Niamh Long;Hira Rizvi

  • An open-label phase 2 trial of dabrafenib plus trametinib in patients with previously treated BRAF V600E–mutant metastatic non-small cell lung cancer

    David Planchard;Benjamin Besse;Harry J M Groen;Pierre-Jean Souquet

  • Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

    Benjamin Besse;Mélinda Charrier;Valérie Lapierre;Eric Dansin

  • Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

    Benjamin J. Solomon;Benjamin Besse;Benjamin Besse;Todd M. Bauer;Enriqueta Felip

  • Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

    Julien Mazières;Solange Peters;Benoit Lepage;Alexis B. Cortot

  • Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

    Roberto Ferrara;Laura Mezquita;Matthieu Texier;Jihene Lahmar

  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

    Alexander Drilon;Geoffrey R. Oxnard;Daniel S.W. Tan;Herbert H.F. Loong

  • A genomics-based classification of human lung tumors

    Danila Seidel;Thomas Zander;Lukas C. Heukamp;Martin Peifer

  • Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.

    Alice T Shaw;Enriqueta Felip;Todd M Bauer;Benjamin Besse;Benjamin Besse

  • CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients

    Fayçal Djenidi;Fayçal Djenidi;Fayçal Djenidi;Julien Adam;Julien Adam;Aïcha Goubar;Aïcha Goubar;Aurélie Durgeau;Aurélie Durgeau;Aurélie Durgeau

  • 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

    J. Vansteenkiste;L. Crinò;C. Dooms;J. Y. Douillard

  • Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor:Results of a Phase II Trial in Patients With Advanced Non-Small-Cell Lung Cancer

    Lecia V. Sequist;Benjamin Besse;Thomas J. Lynch;Vincent A. Miller

Frequent Co-Authors

David Planchard
David Planchard Institut Gustave Roussy
Jean-Charles Soria
Jean-Charles Soria Amgen (United States)
Julien Mazieres
Julien Mazieres Paul Sabatier University
Fabrice Barlesi
Fabrice Barlesi Institut Gustave Roussy
Nicolas Girard
Nicolas Girard Institute Curie
Fabrice Andre
Fabrice Andre Institut Gustave Roussy
Silvia Novello
Silvia Novello University of Turin
Nathalie Chaput
Nathalie Chaput Institut Gustave Roussy
Alice T. Shaw
Alice T. Shaw Harvard University
Enriqueta Felip
Enriqueta Felip Vall d'Hebron Institut de Recerca

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA opens up various alternative and related career options, especially for those considering flexible or online education paths. For example, adn nursing programs are popular choices for students who want to start working as registered nurses more quickly. These programs often take less time than a traditional bachelor’s degree, making nursing more accessible to many.

If you’re interested in the administrative or coding side of healthcare, medical billing and coding schools online offer accredited programs that can lead to rewarding roles in hospitals, clinics, and insurance companies. These online options can often be pursued while working or fulfilling other responsibilities.

Not all nursing programs require the TEAS or HESI entrance exams. Learn more about do you have to take the teas test to get into nursing school and find options that align with your strengths and background.

For those interested in leadership roles, an online healthcare administration degree can provide the skills needed to manage healthcare teams and organizations. Online learning pathways make it easier than ever to advance your healthcare career, whatever your starting point.

Best Scientists Citing Benjamin Besse

Trending Scientists

Recently Published Articles